Pharma

[ad_1] But that portion, measured in other ways, is expanding in the number of pharma professionals dedicated to market access, in the literature count discussing it, and in the number of consultancies dedicated to making these deals. “Value-based has spawned a whole new industry,” says Rob Nauman, principal, BioPharma Advisors. As to why there are